

Antonio Russo

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4488074/publications.pdf>

Version: 2024-02-01

323
papers

11,208
citations

30070

54
h-index

46799

89
g-index

337
all docs

337
docs citations

337
times ranked

16586
citing authors

#	ARTICLE	IF	CITATIONS
1	Adherence to oral hormonal anticancer agents in breast cancer. Tumori, 2023, 109, 262-268.	1.1	1
2	Metabolic disorders and gastroenteropancreatic-neuroendocrine tumors (GEP-NETS): How do they influence each other? An Italian Association of Medical Oncology (AIOM)/ Italian Association of Medical Diabetologists (AMD)/ Italian Society of Endocrinology (SIE)/ Italian Society of Pharmacology (SIF) multidisciplinary consensus position paper. Critical Reviews in Oncology/Hematology, 2022, 169, 103572.	4.4	12
3	The challenge of the Molecular Tumor Board empowerment in clinical oncology practice: A Position Paper on behalf of the AIOM- SIAPEC/IAP-SIBioC-SIC-SIF-SIGU-SIRM Italian Scientific Societies. Critical Reviews in Oncology/Hematology, 2022, 169, 103567.	4.4	26
4	Can the tumor-agnostic evaluation of MSI/MMR status be the common denominator for the immunotherapy treatment of patients with several solid tumors?. Critical Reviews in Oncology/Hematology, 2022, 170, 103597.	4.4	19
5	BRCA1/2 variants of unknown significance in hereditary breast and ovarian cancer (HBOC) syndrome: Looking for the hidden meaning. Critical Reviews in Oncology/Hematology, 2022, 172, 103626.	4.4	6
6	Impact of Different Selection Approaches for Identifying Lynch Syndrome-Related Colorectal Cancer Patients: Unity Is Strength. Frontiers in Oncology, 2022, 12, 827822.	2.8	6
7	The molecular tumor board: a tool for the governance of precision oncology in the real world. Tumori, 2022, 108, 288-290.	1.1	9
8	Safety and effectiveness of gemcitabine for the treatment of classic Kaposi's sarcoma without visceral involvement. Therapeutic Advances in Medical Oncology, 2022, 14, 175883592210868.	3.2	0
9	MUTYH-associated tumor syndrome: The other face of MAP. Oncogene, 2022, 41, 2531-2539.	5.9	10
10	Implementation of preventive and predictive BRCA testing in patients with breast, ovarian, pancreatic, and prostate cancer: a position paper of Italian Scientific Societies. ESMO Open, 2022, 7, 100459.	4.5	26
11	Heart toxicity effects (HTE) of anthracyclines-containing regimens (ACRs) in patients with breast cancer (BC) carrying mutational signature of homologous recombination deficiency (HRD).. Journal of Clinical Oncology, 2022, 40, 10519-10519.	1.6	0
12	Immunometabolic predictive factors in Merkel cell carcinoma (MCC) patients treated with avelumab.. Journal of Clinical Oncology, 2022, 40, e21525-e21525.	1.6	2
13	Is there any room for PD-1 inhibitors in combination with platinum-based chemotherapy as frontline treatment of extensive-stage small cell lung cancer? A systematic review and meta-analysis with indirect comparisons among subgroups and landmark survival analyses. Therapeutic Advances in Medical Oncology, 2021, 13, 175883592110180.	3.2	7
14	Not all KIT 557/558 codons mutations have the same prognostic influence on recurrence-free survival: breaking the exon 11 mutations in gastrointestinal stromal tumors (GISTs). Therapeutic Advances in Medical Oncology, 2021, 13, 175883592110497.	3.2	3
15	Type and Gene Location of KIT Mutations Predict Progression-Free Survival to First-Line Imatinib in Gastrointestinal Stromal Tumors: A Look into the Exon. Cancers, 2021, 13, 993.	3.7	14
16	Role of the HIPPO pathway as potential key player in the cross talk between oncology and cardiology. Critical Reviews in Oncology/Hematology, 2021, 159, 103246.	4.4	3
17	Second medical opinion in oncological setting. Critical Reviews in Oncology/Hematology, 2021, 160, 103282.	4.4	3
18	Prognostic Role of Plasma PD-1, PD-L1, pan-BTN3As and BTN3A1 in Patients Affected by Metastatic Gastrointestinal Stromal Tumors: Can Immune Checkpoints Act as a Sentinel for Short-Term Survival?. Cancers, 2021, 13, 2118.	3.7	23

#	ARTICLE	IF	CITATIONS
19	Arterial Stiffness: Effects of Anticancer Drugs Used for Breast Cancer Women. <i>Frontiers in Physiology</i> , 2021, 12, 661464.	2.8	21
20	INfluenza Vaccine Indication During therapy with Immune checkpoint inhibitors: a multicenter prospective observational study (INVIDIa-2). , 2021, 9, e002619.		17
21	Current treatment options for HER2-positive breast cancer patients with brain metastases. <i>Critical Reviews in Oncology/Hematology</i> , 2021, 161, 103329.	4.4	14
22	Irinotecan or Oxaliplatin: Which is the First Move for the Mate?. <i>Current Medicinal Chemistry</i> , 2021, 28, 3158-3172.	2.4	1
23	Advanced breast cancer at presentation (ABC-p) in octogenarian women (OW): Specific elderly-devoted risk tests (SEDRT) (CARG+CRASH) as new tools to prevent serious/irreversible adverse reactions (AR) in frail patients.. <i>Journal of Clinical Oncology</i> , 2021, 39, e12510-e12510.	1.6	1
24	Antineoplastic dosing in overweight and obese cancer patients: an Associazione Italiana Oncologia Medica (AIOM)/Associazione Medici Diabetologi (AMD)/Societ� Italiana Endocrinologia (SIE)/Societ� Italiana Farmacologia (SIF) multidisciplinary consensus position paper. <i>ESMO Open</i> , 2021, 6, 100153.	4.5	13
25	The molecular profiling of solid tumors by liquid biopsy: a position paper of the AIOM-SIAPEC-IAP-SIBioC-SIC-SIF Italian Scientific Societies. <i>ESMO Open</i> , 2021, 6, 100164.	4.5	69
26	Early prediction of pancreatic cancer from new-onset diabetes: an Associazione Italiana Oncologia Medica (AIOM)/Associazione Medici Diabetologi (AMD)/Societ� Italiana Endocrinologia (SIE)/Societ� Italiana Farmacologia (SIF) multidisciplinary consensus position paper. <i>ESMO Open</i> , 2021, 6, 100155.	4.5	20
27	The prognostic impact of tumor mutational burden (TMB) in the first-line management of advanced non-oncogene addicted non-small-cell lung cancer (NSCLC): a systematic review and meta-analysis of randomized controlled trials. <i>ESMO Open</i> , 2021, 6, 100124.	4.5	75
28	Non-Small Cell Lung Cancer Harboring Concurrent EGFR Genomic Alterations: A Systematic Review and Critical Appraisal of the Double Dilemma. <i>Journal of Molecular Pathology</i> , 2021, 2, 173-196.	1.2	14
29	Prevalence and Spectrum of Germline BRCA1 and BRCA2 Variants of Uncertain Significance in Breast/Ovarian Cancer: Mysterious Signals From the Genome. <i>Frontiers in Oncology</i> , 2021, 11, 682445.	2.8	14
30	Challenges and advances for the treatment of renal cancer patients with brain metastases: From immunological background to upcoming clinical evidence on immune-checkpoint inhibitors. <i>Critical Reviews in Oncology/Hematology</i> , 2021, 163, 103390.	4.4	10
31	Impact of deleterious variants in other genes beyond BRCA1/2 detected in breast/ovarian and pancreatic cancer patients by NGS-based multi-gene panel testing: looking over the hedge. <i>ESMO Open</i> , 2021, 6, 100235.	4.5	38
32	POLE, POLD1, and NTHL1: the last but not the least hereditary cancer-predisposing genes. <i>Oncogene</i> , 2021, 40, 5893-5901.	5.9	34
33	Antitumor Effect of Cabozantinib in Bone Metastatic Models of Renal Cell Carcinoma. <i>Biology</i> , 2021, 10, 781.	2.8	3
34	The tumor-agnostic treatment for patients with solid tumors: a position paper on behalf of the AIOM-SIAPEC/IAP-SIBioC-SIF Italian Scientific Societies. <i>Critical Reviews in Oncology/Hematology</i> , 2021, 165, 103436.	4.4	40
35	Tumor mutational burden on cytological samples: A pilot study. <i>Cancer Cytopathology</i> , 2021, 129, 460-467.	2.4	34
36	Cancer of Exocrine Pancreas. <i>UNIPA Springer Series</i> , 2021, , 645-674.	0.1	0

#	ARTICLE	IF	CITATIONS
37	Liquid Biopsy. UNIPA Springer Series, 2021, , 99-122.	0.1	0
38	Gastrointestinal Stromal Tumors (GISTs). UNIPA Springer Series, 2021, , 1021-1059.	0.1	0
39	Tumor Board and Molecular Tumor Board. UNIPA Springer Series, 2021, , 401-409.	0.1	0
40	Cardio-Oncology. UNIPA Springer Series, 2021, , 309-325.	0.1	0
41	Precision Medicine in Oncology: Glossary of Relevant Scientific Terms. UNIPA Springer Series, 2021, , 411-416.	0.1	0
42	Targeted Therapy. UNIPA Springer Series, 2021, , 181-206.	0.1	0
43	Colorectal Cancer: Metastatic Disease. UNIPA Springer Series, 2021, , 617-633.	0.1	0
44	Tumor Biology and Natural History. UNIPA Springer Series, 2021, , 15-31.	0.1	0
45	Hereditary Cancers and Genetics. UNIPA Springer Series, 2021, , 65-98.	0.1	0
46	Nutrition and Cancer. UNIPA Springer Series, 2021, , 381-389.	0.1	0
47	Effectiveness of a Psychosocial Care Quality Improvement Strategy to Address Quality of Life in Patients With Cancer. JAMA Network Open, 2021, 4, e2128667.	5.9	3
48	S-Adenosylmethionine Supplementation May Reduce Cancer-Related Fatigue: A Prospective Evaluation Using the FACIT-F Questionnaire in Colon Cancer Patients Undergoing Oxaliplatin-Based Chemotherapy Regimens. Chemotherapy, 2021, 66, 1-8.	1.6	1
49	PANHER study: a 20-year treatment outcome analysis from a multicentre observational study of HER2-positive advanced breast cancer patients from the real-world setting. Therapeutic Advances in Medical Oncology, 2021, 13, 175883592110598.	3.2	6
50	An integrated care pathway for cancer patients with diabetes: A proposal from the Italian experience. Diabetes Research and Clinical Practice, 2020, 159, 107721.	2.8	9
51	Distinct HR expression patterns significantly affect the clinical behavior of metastatic HER2+ breast cancer and degree of benefit from novel anti-HER2 agents in the real world setting. International Journal of Cancer, 2020, 146, 1917-1929.	5.1	4
52	Management of metabolic adverse events of targeted therapies and immune checkpoint inhibitors in cancer patients: an Associazione Italiana Oncologia Medica (AIOM)/Associazione Medici Diabetologi (AMD)/Societ� Italiana Farmacologia (SIF) multidisciplinary consensus position paper. Critical Reviews in Oncology/Hematology, 2020, 154, 103066.	4.4	7
53	Reply to: Denosumab for bone health in prostate and breast cancer patients receiving endocrine therapy? A systematic review and a meta-analysis of randomized trials (Galvano et al., J Bone Oncol) Tj ETQq1 1 0.78.4314 rgBT /Overlaid	0.78	43
54	A Lymphocyte MicroRNA Signature as Predictive Biomarker of Immunotherapy Response and Plasma PD-1/PD-L1 Expression Levels in Patients with Metastatic Renal Cell Carcinoma: Pointing towards Epigenetic Reprogramming. Cancers, 2020, 12, 3396.	3.7	41

#	ARTICLE	IF	CITATIONS
55	Symptomatic COVID-19 in advanced-cancer patients treated with immune-checkpoint inhibitors: prospective analysis from a multicentre observational trial by FICOG. <i>Therapeutic Advances in Medical Oncology</i> , 2020, 12, 175883592096846.	3.2	14
56	Baseline plasma levels of soluble PD-1, PD-L1, and BTN3A1 predict response to nivolumab treatment in patients with metastatic renal cell carcinoma: a step toward a biomarker for therapeutic decisions. <i>Oncolmmunology</i> , 2020, 9, 1832348.	4.6	55
57	KRAS mutations testing in non-small cell lung cancer: the role of Liquid biopsy in the basal setting. <i>Journal of Thoracic Disease</i> , 2020, 12, 3836-3843.	1.4	47
58	Cardiovascular Risk in Polycythemia Vera: Thrombotic Risk and Survival: Can Cytoreductive Therapy Be Useful in Patients with Low-Risk Polycythemia Vera with Cardiovascular Risk Factors?. <i>Oncology Research and Treatment</i> , 2020, 43, 526-530.	1.2	16
59	Detection of Germline Mutations in a Cohort of 139 Patients with Bilateral Breast Cancer by Multi-Gene Panel Testing: Impact of Pathogenic Variants in Other Genes beyond BRCA1/2. <i>Cancers</i> , 2020, 12, 2415.	3.7	40
60	Analysis of systemic inflammatory biomarkers in neuroendocrine carcinomas of the lung: prognostic and predictive significance of NLR, LDH, ALI, and LIPI score. <i>Therapeutic Advances in Medical Oncology</i> , 2020, 12, 175883592094237.	3.2	37
61	Impact of BMI on Preoperative Axillary Ultrasound Assessment in Patients With Early Breast Cancer. <i>Anticancer Research</i> , 2020, 40, 7083-7088.	1.1	4
62	The Emerging Therapeutic Landscape of ALK Inhibitors in Non-Small Cell Lung Cancer. <i>Pharmaceuticals</i> , 2020, 13, 474.	3.8	51
63	Loss of HER2 and decreased T-DM1 efficacy in HER2 positive advanced breast cancer treated with dual HER2 blockade: the SePHER Study. <i>Journal of Experimental and Clinical Cancer Research</i> , 2020, 39, 279.	8.6	32
64	Hereditary Breast and Ovarian Cancer in Families from Southern Italy (Sicily)â€”Prevalence and Geographic Distribution of Pathogenic Variants in BRCA1/2 Genes. <i>Cancers</i> , 2020, 12, 1158.	3.7	30
65	Prognostic clinical factors in patients affected by non-small-cell lung cancer receiving Nivolumab. <i>Expert Opinion on Biological Therapy</i> , 2020, 20, 319-326.	3.1	12
66	The significance of epidermal growth factor receptor uncommon mutations in non-small cell lung cancer: A systematic review and critical appraisal. <i>Cancer Treatment Reviews</i> , 2020, 85, 101994.	7.7	89
67	Moving the Target on the Optimal Adjuvant Strategy for Resected Pancreatic Cancers: A Systematic Review with Meta-Analysis. <i>Cancers</i> , 2020, 12, 534.	3.7	15
68	CARDIOVASCULAR RISK IN ESSENTIAL THROMBOCYTHEMIA AND POLYCYTHEMIA VERA: THROMBOTIC RISK AND SURVIVAL. <i>Mediterranean Journal of Hematology and Infectious Diseases</i> , 2020, 12, e2020008.	1.3	14
69	Impact of BMI on HER2+ metastatic breast cancer patients treated with pertuzumab and/or trastuzumab emtansine. Realâ€world evidence. <i>Journal of Cellular Physiology</i> , 2020, 235, 7900-7910.	4.1	19
70	Neutrophil-to-Lymphocyte Ratio (NLR), Platelet-to-Lymphocyte Ratio (PLR), and Outcomes with Nivolumab in Pretreated Non-Small Cell Lung Cancer (NSCLC): A Large Retrospective Multicenter Study. <i>Advances in Therapy</i> , 2020, 37, 1145-1155.	2.9	102
71	Cardiovascular Toxicity in Cancer Patients Treated with Tyrosine Kinase Inhibitors: A Real-World Single-Center Experience. <i>Oncology</i> , 2020, 98, 445-451.	1.9	26
72	COVID-19 Infection in Cancer Patients: How Can Oncologists Deal With These Patients?. <i>Frontiers in Oncology</i> , 2020, 10, 734.	2.8	38

#	ARTICLE	IF	CITATIONS
73	The Essential Thrombocythemia, Thrombotic Risk Stratification, and Cardiovascular Risk Factors. <i>Advances in Hematology</i> , 2020, 2020, 1-5.	1.0	5
74	BRCA1/2 pathogenic variants in triple-negative versus luminal-like breast cancers: genotype-phenotype correlation in a cohort of 531 patients. <i>Therapeutic Advances in Medical Oncology</i> , 2020, 12, 175883592097532.	3.2	34
75	Integrating Liquid Biopsy and Radiomics to Monitor Clonal Heterogeneity of EGFR-Positive Non-Small Cell Lung Cancer. <i>Frontiers in Oncology</i> , 2020, 10, 593831.	2.8	25
76	Fatal Heart Failure Induced By Pazopanib In A Sarcoma Patient Previously Treated With Gemcitabine. <i>Journal of the Saudi Heart Association</i> , 2020, 32, 285-287.	0.4	2
77	Cell-free DNA and exoDNA analysis in metastatic colorectal cancer patients (mCRC).. <i>Journal of Clinical Oncology</i> , 2020, 38, e16093-e16093.	1.6	1
78	Breast Cancer in Men: <i>Oncology</i> . , 2020, , 85-92.		0
79	Denosumab for bone health in prostate and breast cancer patients receiving endocrine therapy? A systematic review and a meta-analysis of randomized trials. <i>Journal of Bone Oncology</i> , 2019, 18, 100252.	2.4	23
80	How do skeletal morbidity rate and special toxicities affect 12-week versus 4-week schedule zoledronic acid efficacy? A systematic review and a meta-analysis of randomized trials. <i>Critical Reviews in Oncology/Hematology</i> , 2019, 142, 68-75.	4.4	4
81	Comparison between thrombotic risk scores in essential thrombocythemia and survival implications. <i>Hematological Oncology</i> , 2019, 37, 434-437.	1.7	10
82	Gut microbiota and cancer: How gut microbiota modulates activity, efficacy and toxicity of antitumoral therapy. <i>Critical Reviews in Oncology/Hematology</i> , 2019, 143, 139-147.	4.4	100
83	BRCA1/2 Molecular Assay for Ovarian Cancer Patients: A Survey through Italian Departments of Oncology and Molecular and Genomic Diagnostic Laboratories. <i>Diagnostics</i> , 2019, 9, 146.	2.6	3
84	How to Deal with Second Line Dilemma in Metastatic Colorectal Cancer? A Systematic Review and Meta-Analysis. <i>Cancers</i> , 2019, 11, 1189.	3.7	4
85	Programmed Death Ligand 1 (PD-L1) as a Predictive Biomarker for Pembrolizumab Therapy in Patients with Advanced Non-Small-Cell Lung Cancer (NSCLC). <i>Advances in Therapy</i> , 2019, 36, 2600-2617.	2.9	80
86	Detection of RAS mutations in circulating tumor DNA: a new weapon in an old war against colorectal cancer. A systematic review of literature and meta-analysis. <i>Therapeutic Advances in Medical Oncology</i> , 2019, 11, 175883591987465.	3.2	27
87	Mitochondrion at the Crossroad Between Nutrients and Epigenome. <i>Frontiers in Endocrinology</i> , 2019, 10, 673.	3.5	7
88	Recommendations for the implementation of BRCA testing in ovarian cancer patients and their relatives. <i>Critical Reviews in Oncology/Hematology</i> , 2019, 140, 67-72.	4.4	51
89	Can the plasma PD-1 levels predict the presence and efficiency of tumor-infiltrating lymphocytes in patients with metastatic melanoma?. <i>Therapeutic Advances in Medical Oncology</i> , 2019, 11, 175883591984887.	3.2	30
90	The HERBA Study: A Retrospective Multi-Institutional Italian Study on Patients With Brain Metastases From HER2-Positive Breast Cancer. <i>Clinical Breast Cancer</i> , 2019, 19, e501-e510.	2.4	11

#	ARTICLE	IF	CITATIONS
91	An update on the conquests and perspectives of cardio-oncology in the field of tumor angiogenesis-targeting TKI-based therapy. <i>Expert Opinion on Drug Safety</i> , 2019, 18, 485-496.	2.4	10
92	<p>Weekly alternate intensive regimen FlrB/FOx in metastatic colorectal cancer patients: an update from clinical practice</p>. <i>OncoTargets and Therapy</i> , 2019, Volume 12, 2159-2170.	2.0	8
93	Epidermal Growth Factor Receptor (EGFR) Cell Expression During Adjuvant Treatment After Transurethral Resection for Non-Muscle-Invasive Bladder Cancer: A New Potential Tool to Identify Patients at Higher Risk of Disease Progression. <i>Clinical Genitourinary Cancer</i> , 2019, 17, e751-e758.	1.9	12
94	Monitoring blood biomarkers to predict nivolumab effectiveness in NSCLC patients. <i>Therapeutic Advances in Medical Oncology</i> , 2019, 11, 175883591983992.	3.2	48
95	Prognostic significance of circulating PD-1, PD-L1, pan-BTN3As, BTN3A1 and BTLA in patients with pancreatic adenocarcinoma. <i>Oncolmmunology</i> , 2019, 8, e1561120.	4.6	92
96	One shot NEPA plus dexamethasone to prevent multiple-day chemotherapy in sarcoma patients. <i>Supportive Care in Cancer</i> , 2019, 27, 3593-3597.	2.2	10
97	Are Long Noncoding RNAs New Potential Biomarkers in Gastrointestinal Stromal Tumors (GISTs)? The Role of H19 and MALAT1. <i>Journal of Oncology</i> , 2019, 2019, 1-7.	1.3	13
98	Management of Ponatinib in Patients with Chronic Myeloid Leukemia with Cardiovascular Risk Factors. <i>Chemotherapy</i> , 2019, 64, 205-209.	1.6	10
99	Eribulin mesylate use as third-line therapy in patients with metastatic breast cancer (VESPRY): a prospective, multicentre, observational study. <i>Therapeutic Advances in Medical Oncology</i> , 2019, 11, 175883591989575.	3.2	13
100	Adipose tissue, angiogenesis and angio-MIR under physiological and pathological conditions. <i>European Journal of Cell Biology</i> , 2019, 98, 53-64.	3.6	14
101	Immunomodulation in Vascularized Composite Allotransplantation. <i>Annals of Plastic Surgery</i> , 2019, 82, 245-251.	0.9	18
102	Insight into genetic susceptibility to male breast cancer by multigene panel testing: Results from a multicenter study in Italy. <i>International Journal of Cancer</i> , 2019, 145, 390-400.	5.1	40
103	Palbociclib plus endocrine therapy in HER2 negative, hormonal receptorâ€positive, advanced breast cancer: A realâ€world experience. <i>Journal of Cellular Physiology</i> , 2019, 234, 7708-7717.	4.1	21
104	Role of tumor-infiltrating lymphocytes in patients with solid tumors: Can a drop dig a stone?. <i>Cellular Immunology</i> , 2019, 343, 103753.	3.0	187
105	Evaluation of CYP17A1 and CYP1B1 polymorphisms in male breast cancer risk. <i>Endocrine Connections</i> , 2019, 8, 1224-1229.	1.9	6
106	Activity and safety of temozolomide in advanced adrenocortical carcinoma patients. <i>European Journal of Endocrinology</i> , 2019, 181, 681-689.	3.7	30
107	Cardiovascular Damage in Clinical Trials. <i>Current Clinical Pathology</i> , 2019, , 205-217.	0.0	0
108	Effects of Dietary Restriction on Cancer Development and Progression. , 2019, , 1355-1373.		0

#	ARTICLE	IF	CITATIONS
109	A novel predictive biomarker of immunotherapy response in metastatic renal cell carcinoma (mRCC): The lymphocyte microRNA expression profile.. Journal of Clinical Oncology, 2019, 37, e16109-e16109.	1.6	0
110	Molecular profiling of pancreatic neuroendocrine tumors (pNETS) and the clinical potential. Expert Review of Gastroenterology and Hepatology, 2018, 12, 471-478.	3.0	5
111	A possible role of FANCM mutations in male breast cancer susceptibility: Results from a multicenter study in Italy. Breast, 2018, 38, 92-97.	2.2	23
112	Looking for the best immuneâ€checkpoint inhibitor in preâ€treated NSCLC patients: An indirect comparison between nivolumab, pembrolizumab and atezolizumab. International Journal of Cancer, 2018, 142, 1277-1284.	5.1	81
113	A single-institution retrospective analysis of metachronous and synchronous metastatic bronchial neuroendocrine tumors. Journal of Thoracic Disease, 2018, 10, 3928-3939.	1.4	15
114	Monoclonal antibodies for the treatment of non-hematological tumors: a safety review. Expert Opinion on Drug Safety, 2018, 17, 1197-1209.	2.4	11
115	Contribution of MUTYH Variants to Male Breast Cancer Risk: Results From a Multicenter Study in Italy. Frontiers in Oncology, 2018, 8, 583.	2.8	25
116	Circular RNA in Exosomes. Advances in Experimental Medicine and Biology, 2018, 1087, 109-117.	1.6	139
117	The Era of PARP inhibitors in ovarian cancer: â€œClass Actionâ€or not? A systematic review and meta-analysis. Critical Reviews in Oncology/Hematology, 2018, 131, 83-89.	4.4	37
118	The diagnostic accuracy of circulating tumor DNA for the detection of EGFR-T790M mutation in NSCLC: a systematic review and meta-analysis. Scientific Reports, 2018, 8, 13379.	3.3	66
119	Nine weeks versus 1 year adjuvant trastuzumab in combination with chemotherapy: final results of the phase III randomized Short-HER study. Annals of Oncology, 2018, 29, 2328-2333.	1.2	124
120	Spheroids from adiposeâ€derived stem cells exhibit an miRNA profile of highly undifferentiated cells. Journal of Cellular Physiology, 2018, 233, 8778-8789.	4.1	20
121	The changing scenario of 1st line therapy in non-oncogene addicted NSCLCs in the era of immunotherapy. Critical Reviews in Oncology/Hematology, 2018, 130, 1-12.	4.4	16
122	Cardiotoxicity mechanisms of the combination of BRAF-inhibitors and MEK-inhibitors. , 2018, 192, 65-73.		35
123	The use of SAME in chemotherapy-induced liver injury. Critical Reviews in Oncology/Hematology, 2018, 130, 70-77.	4.4	21
124	Dose-finding study of oxaliplatin associated to capecitabine-based preoperative chemoradiotherapy in locally advanced rectal cancer. Oncotarget, 2018, 9, 17906-17914.	1.8	5
125	Dose-finding study of intensive weekly alternating schedule of docetaxel, 5-fluorouracil, and oxaliplatin, FD/FOx regimen, in metastatic gastric cancer. Oncotarget, 2018, 9, 20339-20350.	1.8	5
126	Real life triplet Flr/FOx chemotherapy in first-line metastatic pancreatic ductal adenocarcinoma patients: recommended schedule for expected activity and safety and phase II study. Oncotarget, 2018, 9, 31861-31876.	1.8	4

#	ARTICLE	IF	CITATIONS
127	Metastatic Site Location Influences the Diagnostic Accuracy of ctDNA EGFR- Mutation Testing in NSCLC Patients: a Pooled Analysis. <i>Current Cancer Drug Targets</i> , 2018, 18, 697-705.	1.6	34
128	Phospho-Akt overexpression is prognostic and can be used to tailor the synergistic interaction of Akt inhibitors with gemcitabine in pancreatic cancer. <i>Journal of Hematology and Oncology</i> , 2017, 10, 9.	17.0	65
129	Risk Perception and Psychological Distress in Genetic Counselling for Hereditary Breast and/or Ovarian Cancer. <i>Journal of Genetic Counseling</i> , 2017, 26, 999-1007.	1.6	32
130	EGFR inhibition in NSCLC: New findings and opened questions?. <i>Critical Reviews in Oncology/Hematology</i> , 2017, 112, 126-135.	4.4	22
131	Effects of Dietary Restriction on Cancer Development and Progression. , 2017, , 1-19.		1
132	Liquid Biopsy in Esophageal, Gastric, and Pancreatic Cancers. <i>Current Clinical Pathology</i> , 2017, , 137-150.	0.0	0
133	Olaratumab: PDGFR- α inhibition as a novel tool in the treatment of advanced soft tissue sarcomas. <i>Critical Reviews in Oncology/Hematology</i> , 2017, 118, 1-6.	4.4	16
134	Liquid Biopsy in Cancer Patients: The Hand Lens to Investigate Tumor Evolution. <i>Current Clinical Pathology</i> , 2017, , 1-5.	0.0	2
135	Liquid Biopsy in Non-Small Cell Lung Cancer (NSCLC). <i>Current Clinical Pathology</i> , 2017, , 103-115.	0.0	4
136	Cancer Clonal Evolution and Intra-tumor Heterogeneity. <i>Current Clinical Pathology</i> , 2017, , 27-39.	0.0	1
137	Liquid Biopsy in Colorectal Cancer. <i>Current Clinical Pathology</i> , 2017, , 117-124.	0.0	0
138	Liquid Biopsy in Gynecological Cancers. <i>Current Clinical Pathology</i> , 2017, , 85-93.	0.0	0
139	The effects of enzalutamide and abiraterone on skeletal related events and bone radiological progression free survival in castration resistant prostate cancer patients: An indirect comparison of randomized controlled trials. <i>Critical Reviews in Oncology/Hematology</i> , 2017, 120, 227-233.	4.4	15
140	Anticancer therapy-induced vascular toxicity: VEGF inhibition and beyond. <i>International Journal of Cardiology</i> , 2017, 227, 11-17.	1.7	64
141	Whole-exome sequencing and targeted gene sequencing provide insights into the role of <i>PALB2</i> as a male breast cancer susceptibility gene. <i>Cancer</i> , 2017, 123, 210-218.	4.1	31
142	Personalization of regorafenib treatment in metastatic gastrointestinal stromal tumours in real-life clinical practice. <i>Therapeutic Advances in Medical Oncology</i> , 2017, 9, 731-739.	3.2	20
143	Cabozantinib targets bone microenvironment modulating human osteoclast and osteoblast functions. <i>Oncotarget</i> , 2017, 8, 20113-20121.	1.8	36
144	Targeting Angiogenesis in Biliary Tract Cancers: An Open Option. <i>International Journal of Molecular Sciences</i> , 2017, 18, 418.	4.1	47

#	ARTICLE	IF	CITATIONS
145	Cardiotoxic Effects of Anti-VEGFR Tyrosine Kinase Inhibitors. , 2017, , 69-89.		7
146	Exosomes as diagnostic and predictive biomarkers in lung cancer. Journal of Thoracic Disease, 2017, 9, S1373-S1382.	1.4	90
147	Liquid Biopsy in Gastrointestinal Stromal Tumor. Current Clinical Pathology, 2017, , 151-159.	0.0	1
148	Clinical parameters to guide decision-making in elderly metastatic colorectal cancer patients treated with intensive cytotoxic and anti-angiogenic therapy. Oncotarget, 2017, 8, 37875-37883.	1.8	12
149	“Back to a false normality” new intriguing mechanisms of resistance to PARP inhibitors. Oncotarget, 2017, 8, 23891-23904.	1.8	24
150	Analysis of miRNA expression profile induced by short term starvation in breast cancer cells treated with doxorubicin. Oncotarget, 2017, 8, 71924-71932.	1.8	26
151	A retrospective multicentric observational study of trastuzumab emtansine in HER2 positive metastatic breast cancer: a real-world experience. Oncotarget, 2017, 8, 56921-56931.	1.8	53
152	Effects of erybuline/capecitabine (EC) treatment in very elderly women (VEW) with MBC.. Journal of Clinical Oncology, 2017, 35, e12508-e12508.	1.6	0
153	Analysis of tissue and circulating microRNA expression during metaplastic transformation of the esophagus. Oncotarget, 2016, 7, 47821-47830.	1.8	36
154	Chemotherapy cardiotoxicity. Journal of Cardiovascular Medicine, 2016, 17, 270-275.	1.5	15
155	Recommendations for the implementation of BRCA testing in the care and treatment pathways of ovarian cancer patients. Future Oncology, 2016, 12, 2071-2075.	2.4	21
156	Neutrophil/lymphocyte ratio helps select metastatic pancreatic cancer patients benefitting from oxaliplatin. Cancer Biomarkers, 2016, 17, 335-345.	1.7	13
157	Dietary restriction: could it be considered as speed bump on tumor progression road?. Tumor Biology, 2016, 37, 7109-7118.	1.8	24
158	Male breast cancer in BRCA1 and BRCA2 mutation carriers: pathology data from the Consortium of Investigators of Modifiers of BRCA1/2. Breast Cancer Research, 2016, 18, 15.	5.0	88
159	Central nervous system involvement in ALK-rearranged NSCLC: promising strategies to overcome crizotinib resistance. Expert Review of Anticancer Therapy, 2016, 16, 615-623.	2.4	21
160	Non-coding RNAs Functioning in Colorectal Cancer Stem Cells. Advances in Experimental Medicine and Biology, 2016, 937, 93-108.	1.6	24
161	The resistance related to targeted therapy in malignant pleural mesothelioma: Why has not the target been hit yet?. Critical Reviews in Oncology/Hematology, 2016, 107, 20-32.	4.4	31
162	Relationship between anxiety level and radiological investigation. Comparison among different diagnostic imaging exams in a prospective single-center study. Radiologia Medica, 2016, 121, 763-768.	7.7	36

#	ARTICLE	IF	CITATIONS
163	Involvement of Non-coding RNAs in Chemo- and Radioresistance of Colorectal Cancer. <i>Advances in Experimental Medicine and Biology</i> , 2016, 937, 207-228.	1.6	55
164	Nintedanib in NSCLC: evidence to date and place in therapy. <i>Therapeutic Advances in Medical Oncology</i> , 2016, 8, 188-197.	3.2	19
165	A headlight on liquid biopsies: a challenging tool for breast cancer management. <i>Tumor Biology</i> , 2016, 37, 4263-4273.	1.8	18
166	Can KRAS and BRAF mutations limit the benefit of liver resection in metastatic colorectal cancer patients? A systematic review and meta-analysis. <i>Critical Reviews in Oncology/Hematology</i> , 2016, 99, 150-157.	4.4	81
167	Absence of germline CDKN2A mutation in Sicilian patients with familial malignant melanoma: Could it be a population-specific genetic signature?. <i>Cancer Biology and Therapy</i> , 2016, 17, 83-90.	3.4	18
168	HepatomirNoma: The proposal of a new network of targets for diagnosis, prognosis and therapy in hepatocellular carcinoma. <i>Critical Reviews in Oncology/Hematology</i> , 2016, 97, 312-321.	4.4	30
169	The potential of neurotrophic tyrosine kinase (NTRK) inhibitors for treating lung cancer. <i>Expert Opinion on Investigational Drugs</i> , 2016, 25, 385-392.	4.1	26
170	Anti-angiogenic drugs for second-line treatment of NSCLC patients: just new pawns on the chessboard?. <i>Expert Opinion on Biological Therapy</i> , 2016, 16, 1-5.	3.1	8
171	Triple negative breast cancer: shedding light onto the role of pi3k/akt/mTOR pathway. <i>Oncotarget</i> , 2016, 7, 60712-60722.	1.8	103
172	Imatinib dose escalation versus sunitinib as a second line treatment in KIT exon 11 mutated GIST: a retrospective analysis. <i>Oncotarget</i> , 2016, 7, 69412-69419.	1.8	17
173	Beyond evidence-based data: scientific rationale and tumor behavior to drive sequential and personalized therapeutic strategies for the treatment of metastatic renal cell carcinoma. <i>Oncotarget</i> , 2016, 7, 21259-21271.	1.8	16
174	PD-L1 expression as predictive biomarker in patients with NSCLC: a pooled analysis. <i>Oncotarget</i> , 2016, 7, 19738-19747.	1.8	134
175	The comparison of outcomes from tyrosine kinase inhibitor monotherapy in second- or third-line for advanced non-small-cell lung cancer patients with wild-type or unknown EGFR status. <i>Oncotarget</i> , 2016, 7, 35803-35812.	1.8	9
176	Can the microRNA expression profile help to identify novel targets for zoledronic acid in breast cancer?. <i>Oncotarget</i> , 2016, 7, 29321-29332.	1.8	23
177	KRAS and BRAF as prognostic biomarkers in patients undergoing surgical resection of colorectal cancer liver metastasis: A systematic review and meta-analysis.. <i>Journal of Clinical Oncology</i> , 2016, 34, 3565-3565.	1.6	0
178	Adding chemotherapy to TKI: can we improve first-line treatment for EGFR-mutated NSCLC patients?. <i>Translational Cancer Research</i> , 2016, 5, S1413-S1416.	1.0	0
179	Adjuvant Chemoradiation Therapy in Gastric Cancer: Critically Reviewing the Past and Visualizing the Next Step Forward. <i>Gastroenterology Research and Practice</i> , 2015, 2015, 1-9.	1.5	3
180	What links BRAF to the heart function? new insights from the cardiotoxicity of BRAF inhibitors in cancer treatment. <i>Oncotarget</i> , 2015, 6, 35589-35601.	1.8	57

#	ARTICLE	IF	CITATIONS
181	MicroRNA in pancreatic adenocarcinoma: predictive/prognostic biomarkers or therapeutic targets?. <i>Oncotarget</i> , 2015, 6, 23323-23341.	1.8	65
182	Conquests and perspectives of cardio-oncology in the field of tumor angiogenesis-targeting tyrosine kinase inhibitor-based therapy. <i>Expert Opinion on Drug Safety</i> , 2015, 14, 253-267.	2.4	43
183	Bone metastases in patients with metastatic renal cell carcinoma: are they always associated with poor prognosis?. <i>Journal of Experimental and Clinical Cancer Research</i> , 2015, 34, 10.	8.6	65
184	What can platinum offer yet in the treatment of PS2 NSCLC patients? A systematic review and meta-analysis. <i>Critical Reviews in Oncology/Hematology</i> , 2015, 95, 306-317.	4.4	27
185	Novel and known genetic variants for male breast cancer risk at 8q24.21, 9p21.3, 11q13.3 and 14q24.1: Results from a multicenter study in Italy. <i>European Journal of Cancer</i> , 2015, 51, 2289-2295.	2.8	25
186	Hepatocellular carcinoma treatment over sorafenib: epigenetics, microRNAs and microenvironment. Is there a light at the end of the tunnel?. <i>Expert Opinion on Therapeutic Targets</i> , 2015, 19, 1623-1635.	3.4	58
187	Entrectinib: a potent new TRK, ROS1, and ALK inhibitor. <i>Expert Opinion on Investigational Drugs</i> , 2015, 24, 1493-1500.	4.1	117
188	Prognostic and predictive biomarkers for targeted therapy in NSCLC: for whom the bell tolls?. <i>Expert Opinion on Biological Therapy</i> , 2015, 15, 1553-1566.	3.1	22
189	Farletuzumab for NSCLC: exploiting a well-known metabolic pathway for a new therapeutic strategy. <i>Expert Opinion on Investigational Drugs</i> , 2015, 24, 125-132.	4.1	5
190	The prevalent KRAS exon 2 c.35 G>A mutation in metastatic colorectal cancer patients: A biomarker of worse prognosis and potential benefit of bevacizumab-containing intensive regimens?. <i>Critical Reviews in Oncology/Hematology</i> , 2015, 93, 190-202.	4.4	24
191	Monoclonal antibodies for the treatment of non-haematological tumours: update of an expanding scenario. <i>Expert Opinion on Biological Therapy</i> , 2015, 15, 45-59.	3.1	8
192	Targeted Therapies in Melanoma. <i>Current Clinical Pathology</i> , 2015, , 211-227.	0.0	4
193	Exosomes isolation and characterization in non small cell lung carcinoma patients: Proof of concept study.. <i>Journal of Clinical Oncology</i> , 2015, 33, 11101-11101.	1.6	1
194	The Changes of Lipid Metabolism in Advanced Renal Cell Carcinoma Patients Treated with Everolimus: A New Pharmacodynamic Marker?. <i>PLoS ONE</i> , 2015, 10, e0120427.	2.5	9
195	New findings on primary and acquired resistance to anti-EGFR therapy in metastatic colorectal cancer: do all roads lead to RAS?. <i>Oncotarget</i> , 2015, 6, 24780-24796.	1.8	77
196	Prognostic significance of K-Ras mutation rate in metastatic colorectal cancer patients. <i>Oncotarget</i> , 2015, 6, 31604-31612.	1.8	30
197	Targeted Therapies for Colorectal Cancer. <i>Current Clinical Pathology</i> , 2015, , 147-162.	0.0	0
198	Targeted Therapies for Non-Small Cell Lung Cancer. <i>Current Clinical Pathology</i> , 2015, , 89-101.	0.0	1

#	ARTICLE	IF	CITATIONS
199	Natural History of Malignant Bone Disease in Hepatocellular Carcinoma: Final Results of a Multicenter Bone Metastasis Survey. PLoS ONE, 2014, 9, e105268.	2.5	33
200	Pharmacogenomics of cetuximab in metastatic colorectal carcinoma. Pharmacogenomics, 2014, 15, 1701-1715.	1.3	4
201	Looking for a new panacea in ALK-rearranged NSCLC: may be Ceritinib?. Expert Opinion on Therapeutic Targets, 2014, 18, 983-985.	3.4	7
202	Germline copy number variation in the <i>YTHDC2</i> gene: does it have a role in finding a novel potential molecular target involved in pancreatic adenocarcinoma susceptibility?. Expert Opinion on Therapeutic Targets, 2014, 18, 841-850.	3.4	44
203	Immunotherapy for recurrent ovarian cancer: a further piece of the puzzle or a striking strategy?. Expert Opinion on Biological Therapy, 2014, 14, 103-114.	3.1	6
204	Association of SULT1A1 Arg213His polymorphism with male breast cancer risk: results from a multicenter study in Italy. Breast Cancer Research and Treatment, 2014, 148, 623-628.	2.5	7
205	Are erlotinib and gefitinib interchangeable, opposite or complementary for non-small cell lung cancer treatment? Biological, pharmacological and clinical aspects. Critical Reviews in Oncology/Hematology, 2014, 89, 300-313.	4.4	68
206	The role of targeted therapy for gastrointestinal tumors. Expert Review of Gastroenterology and Hepatology, 2014, 8, 875-885.	3.0	27
207	Liquid biopsies in lung cancer: The new ambrosia of researchers. Biochimica Et Biophysica Acta: Reviews on Cancer, 2014, 1846, 539-546.	7.4	123
208	Immunotherapy: is a minor god yet in the pantheon of treatments for lung cancer?. Expert Review of Anticancer Therapy, 2014, 14, 1173-1187.	2.4	25
209	How to find the Ariadne's thread in the labyrinth of salvage treatment options for metastatic colorectal cancer?. Expert Opinion on Biological Therapy, 2014, 14, 743-748.	3.1	15
210	Molecular target therapy for bone metastasis: starting a new era with denosumab, a RANKL inhibitor. Expert Opinion on Biological Therapy, 2014, 14, 15-26.	3.1	17
211	Novel therapeutic strategies for patients with NSCLC that do not respond to treatment with EGFR inhibitors. Cancer Treatment Reviews, 2014, 40, 990-1004.	7.7	70
212	Ramucirumab and its use in gastric cancer treatment. Drugs of Today, 2014, 50, 613.	1.1	3
213	Targeted Therapies in Hepatocellular Carcinoma. Current Medicinal Chemistry, 2014, 21, 966-974.	2.4	19
214	Impact of microRNAs in Resistance to Chemotherapy and Novel Targeted Agents in Non-Small Cell Lung Cancer. Current Pharmaceutical Biotechnology, 2014, 15, 475-485.	1.6	54
215	The Role of cMet in Non-Small Cell Lung Cancer Resistant to EGFR Inhibitors: Did We Really Find the Target?. Current Drug Targets, 2014, 15, 1284-1292.	2.1	10
216	ALK and crizotinib: after the honeymoon what else? Resistance mechanisms and new therapies to overcome it. Translational Lung Cancer Research, 2014, 3, 250-61.	2.8	44

#	ARTICLE	IF	CITATIONS
217	Effects of PPAR α agonists on the expression of leptin and vascular endothelial growth factor in breast cancer cells. <i>Journal of Cellular Physiology</i> , 2013, 228, 1368-1374.	4.1	29
218	Dilemma in metastatic colorectal cancer: VEGF versus EGRF targeting. <i>Expert Opinion on Therapeutic Targets</i> , 2013, 17, 869-871.	3.4	8
219	Management of Toxicity Induced by Anti-EGFR Therapy in Metastatic Colorectal Cancer. <i>Current Colorectal Cancer Reports</i> , 2013, 9, 250-260.	0.5	1
220	HIF-1 is involved in the negative regulation of AURKA expression in breast cancer cell lines under hypoxic conditions. <i>Breast Cancer Research and Treatment</i> , 2013, 140, 505-517.	2.5	29
221	Role of curcumin in idiopathic pulmonary arterial hypertension treatment: A new therapeutic possibility. <i>Medical Hypotheses</i> , 2013, 81, 923-926.	1.5	18
222	Zoledronic Acid Induces a Significant Decrease of Circulating Endothelial Cells and Circulating Endothelial Precursor Cells in the Early Prostate Cancer Neoadjuvant Setting. <i>Oncology</i> , 2013, 85, 342-347.	1.9	11
223	Genetic and molecular characterization of the human Osteosarcoma 3AB α OS cancer stem cell line: A possible model for studying osteosarcoma origin and stemness. <i>Journal of Cellular Physiology</i> , 2013, 228, 1189-1201.	4.1	46
224	Co-expression of CD133 ⁺ /CD44 ⁺ in human colon cancer and liver metastasis. <i>Journal of Cellular Physiology</i> , 2013, 228, 408-415.	4.1	45
225	The molecular changes driving the carcinogenesis in Barrett's esophagus: Which came first, the chicken or the egg?. <i>Critical Reviews in Oncology/Hematology</i> , 2013, 86, 278-289.	4.4	8
226	Effects of anti-miR-182 on TSP-1 expression in human colon cancer cells: there is a sense in antisense?. <i>Expert Opinion on Therapeutic Targets</i> , 2013, 17, 1249-1261.	3.4	41
227	Monoclonal antibodies in gastrointestinal cancers. <i>Expert Opinion on Biological Therapy</i> , 2013, 13, 889-900.	3.1	18
228	TNF α gene promoter polymorphisms and risk of venous thromboembolism in gastrointestinal cancer patients undergoing chemotherapy. <i>Annals of Oncology</i> , 2013, 24, 2571-2575.	1.2	16
229	Hypoxia and Human Genome Stability: Downregulation of BRCA2 Expression in Breast Cancer Cell Lines. <i>BioMed Research International</i> , 2013, 2013, 1-8.	1.9	32
230	SULT1A1 gene deletion in BRCA2-associated male breast cancer: a link between genes and environmental exposures?. <i>Journal of Cellular and Molecular Medicine</i> , 2013, 17, 605-607.	3.6	8
231	The role of macrophages polarization in predicting prognosis of radically resected gastric cancer patients. <i>Journal of Cellular and Molecular Medicine</i> , 2013, 17, 1415-1421.	3.6	76
232	Circulating miR-22, miR-24 and miR-34a as novel predictive biomarkers to pemetrexed-based chemotherapy in advanced non small cell lung cancer. <i>Journal of Cellular Physiology</i> , 2013, 229, n/a-n/a.	4.1	96
233	High density of tryptase α -positive mast cells in human colorectal cancer: a poor prognostic factor related to protease α -activated receptor 2 expression. <i>Journal of Cellular and Molecular Medicine</i> , 2013, 17, 1025-1037.	3.6	80
234	BIBF 1120/nintedanib: a new triple angiokinase inhibitor-directed therapy in patients with non-small cell lung cancer. <i>Expert Opinion on Investigational Drugs</i> , 2013, 22, 1081-1088.	4.1	28

#	ARTICLE	IF	CITATIONS
235	Analysis of Germline Gene Copy Number Variants of Patients with Sporadic Pancreatic Adenocarcinoma Reveals Specific Variations. <i>Oncology</i> , 2013, 85, 306-311.	1.9	15
236	Natural History of Malignant Bone Disease in Renal Cancer: Final Results of an Italian Bone Metastasis Survey. <i>PLoS ONE</i> , 2013, 8, e83026.	2.5	66
237	MicroRNAs in colorectal cancer stem cells: new regulators of cancer stemness?. <i>Oncogenesis</i> , 2012, 1, e32-e32.	4.9	45
238	How Much of Familial Breast Cancer Risk is Currently Explained by the Known Genes?. <i>Current Women's Health Reviews</i> , 2012, 8, 38-43.	0.2	0
239	Identification and Characterization of BRCA1 and BRCA2 Founder Mutations. <i>Current Women's Health Reviews</i> , 2012, 8, 17-22.	0.2	2
240	What are the Cancer Risks in BRCA Carriers Apart from Those Regarding the Breast and the Ovary?. <i>Current Women's Health Reviews</i> , 2012, 8, 65-71.	0.2	1
241	Editorial from Guest Editor [Hot Topic: Familial and Hereditary Breast and Ovarian Tumors (Guest) Tj ETQq1 1 0.784314 rgBT /Overlo	0.2	0
242	Cetuximab rechallenge in metastatic colorectal cancer patients: how to come away from acquired resistance?. <i>Annals of Oncology</i> , 2012, 23, 2313-2318.	1.2	170
243	Janus kinase (JAK) 2 V617F mutation as the cause of primary thrombocythemia in acromegaly with severe visceromegaly and divergence between growth hormone and insulin-like growth factor-1 concentrations during the follow-up: causal or casual association?. <i>Growth Hormone and IGF Research</i> , 2012, 22, 92-96.	1.1	1
244	Analysis of molecular mechanisms and anti-tumoural effects of zoledronic acid in breast cancer cells. <i>Journal of Cellular and Molecular Medicine</i> , 2012, 16, 2186-2195.	3.6	23
245	Breast cancer genome-wide association studies: there is strength in numbers. <i>Oncogene</i> , 2012, 31, 2121-2128.	5.9	96
246	The role of microRNAs in cancer: diagnostic and prognostic biomarkers and targets of therapies. <i>Expert Opinion on Therapeutic Targets</i> , 2012, 16, S103-S109.	3.4	117
247	Clinical and pathologic characteristics of BRCA-positive and BRCA-negative male breast cancer patients: results from a collaborative multicenter study in Italy. <i>Breast Cancer Research and Treatment</i> , 2012, 134, 411-418.	2.5	73
248	PML as a potential predictive factor of oxaliplatin/fluoropyrimidine-based first line chemotherapy efficacy in colorectal cancer patients. <i>Journal of Cellular Physiology</i> , 2012, 227, 927-933.	4.1	5
249	Monoclonal antibodies and antibody fragments: state of the art and future perspectives in the treatment of non-haematological tumors. <i>Expert Opinion on Biological Therapy</i> , 2011, 11, 1433-1445.	3.1	15
250	EGFR genomic alterations in cancer prognostic and predictive values. <i>Frontiers in Bioscience - Elite</i> , 2011, E3, 879-887.	1.8	29
251	Predicting Efficacy and Toxicity in the Era of Targeted Therapy: Focus on Anti-EGFR and Anti-VEGF Molecules. <i>Current Drug Metabolism</i> , 2011, 12, 944-955.	1.2	15
252	Prognostic role of human equilibrative transporter 1 (hENT1) in patients with resected gastric cancer. <i>Journal of Cellular Physiology</i> , 2010, 223, 384-388.	4.1	34

#	ARTICLE	IF	CITATIONS
253	HER2-positive male breast cancer: an update. <i>Breast Cancer: Targets and Therapy</i> , 2010, 2, 45.	1.8	15
254	Early Skin Toxicity as a Predictive Factor for Tumor Control in Hepatocellular Carcinoma Patients Treated with Sorafenib. <i>Oncologist</i> , 2010, 15, 85-92.	3.7	162
255	Anti-endothelin drugs in solid tumors. <i>Expert Opinion on Emerging Drugs</i> , 2010, 15, 27-40.	2.4	16
256	The Clinical Significance of Unknown Sequence Variants in BRCA Genes. <i>Cancers</i> , 2010, 2, 1644-1660.	3.7	29
257	Drug-Related Cardiotoxicity for the Treatment of Haematological Malignancies in Elderly. <i>Current Pharmaceutical Design</i> , 2010, 16, 2872-2879.	1.9	6
258	Cetuximab plus FOLFOX-4 in Untreated Patients with Advanced Colorectal Cancer: A Gruppo Oncologico dell'™Italia Meridionale Multicenter Phase II Study. <i>Oncology</i> , 2010, 79, 415-422.	1.9	16
259	Bortezomib: A New Pro-Apoptotic Agent in Cancer Treatment. <i>Current Cancer Drug Targets</i> , 2010, 10, 55-67.	1.6	37
260	R-Roscovitine (Seliciclib) prevents DNA damage-induced cyclin A1 upregulation and hinders non-homologous end-joining (NHEJ) DNA repair. <i>Molecular Cancer</i> , 2010, 9, 208.	19.2	13
261	Driver mutations and differential sensitivity to targeted therapies: a new approach to the treatment of lung adenocarcinoma. <i>Cancer Treatment Reviews</i> , 2010, 36, S21-S29.	7.7	128
262	Prognostic vs predictive molecular biomarkers in colorectal cancer: is KRAS and BRAF wild type status required for anti-EGFR therapy?. <i>Cancer Treatment Reviews</i> , 2010, 36, S56-S61.	7.7	103
263	Gefitinib in lung cancer therapy: Clinical results, predictive markers of response and future perspectives. <i>Cancer Biology and Therapy</i> , 2009, 8, 206-212.	3.4	10
264	KRAS mutations and sensitivity to anti-EGFR monoclonal antibodies in metastatic colorectal carcinoma: an open issue. <i>Expert Opinion on Biological Therapy</i> , 2009, 9, 565-577.	3.1	10
265	The Long and Winding Road to Useful Predictive Factors for Anti-EGFR Therapy in Metastatic Colorectal Carcinoma: The KRAS/BRAF Pathway. <i>Oncology</i> , 2009, 77, 57-68.	1.9	49
266	Gemcitabine-based doublets versus single-agent therapy for elderly patients with advanced nonsmall cell lung cancer. <i>Cancer</i> , 2009, 115, 1924-1931.	4.1	24
267	Bevacizumab in association with de Gramont 5-fluorouracil/folinic acid in patients with oxaliplatin-, irinotecan-, and cetuximab-refractory colorectal cancer. <i>Cancer</i> , 2009, 115, 4849-4856.	4.1	30
268	Expression of angiogenic regulators, VEGF and leptin, is regulated by the EGF/PI3K/STAT3 pathway in colorectal cancer cells. <i>Journal of Cellular Physiology</i> , 2009, 221, 189-194.	4.1	50
269	Assessment of "grading" with Ki67 and c-kit immunohistochemical expressions may be a helpful tool in management of patients with flat epithelial atypia (FEA) and columnar cell lesions (CCLs) on core breast biopsy. <i>Journal of Cellular Physiology</i> , 2009, 221, 343-349.	4.1	12
270	Is BRCA1-5083del19, identified in breast cancer patients of Sicilian origin, a Calabrian founder mutation?. <i>Breast Cancer Research and Treatment</i> , 2009, 113, 67-70.	2.5	23

#	ARTICLE	IF	CITATIONS
271	Hereditary ovarian cancer. <i>Critical Reviews in Oncology/Hematology</i> , 2009, 69, 28-44.	4.4	94
272	The Dark Side of the Moon: The PI3K/PTEN/AKT Pathway in Colorectal Carcinoma. <i>Oncology</i> , 2009, 77, 69-74.	1.9	16
273	Quantitative Fluorescence Determination of Long-Fragment DNA in Stool as a Marker for the Early Detection of Colorectal Cancer. <i>Analytical Cellular Pathology</i> , 2009, 31, 11-17.	1.4	1
274	BRCA1/BRCA2 rearrangements and CHEK2 common mutations are infrequent in Italian male breast cancer cases. <i>Breast Cancer Research and Treatment</i> , 2008, 110, 161-167.	2.5	42
275	Mechanism of leptin expression in breast cancer cells: role of hypoxia-inducible factor-1 β . <i>Oncogene</i> , 2008, 27, 540-547.	5.9	79
276	Insulin-Dependent Leptin Expression in Breast Cancer Cells. <i>Cancer Research</i> , 2008, 68, 4919-4927.	0.9	62
277	Could starvation minimize chemotherapy-induced toxicities?. <i>Expert Opinion on Therapeutic Targets</i> , 2008, 12, 1205-1207.	3.4	3
278	HPV in oral squamous cell carcinoma vs head and neck squamous cell carcinoma biopsies: a meta-analysis (1988-2007). <i>Annals of Oncology</i> , 2008, 19, 1681-1690.	1.2	278
279	High Concordance of KRAS Status Between Primary Colorectal Tumors and Related Metastatic Sites: Implications for Clinical Practice. <i>Oncologist</i> , 2008, 13, 1270-1275.	3.7	218
280	Early Magnesium Reduction in Advanced Colorectal Cancer Patients Treated with Cetuximab Plus Irinotecan as Predictive Factor of Efficacy and Outcome. <i>Clinical Cancer Research</i> , 2008, 14, 4219-4224.	7.0	57
281	The role of Aurora-A inhibitors in cancer therapy. <i>Annals of Oncology</i> , 2007, 18, vi47-vi52.	1.2	50
282	4843delC of the BRCA1 gene is a possible founder mutation in Southern Italy (Sicily). <i>Annals of Oncology</i> , 2007, 18, vi99-vi102.	1.2	7
283	Targeting apoptosis in solid tumors: the role of bortezomib from preclinical to clinical evidence. <i>Expert Opinion on Therapeutic Targets</i> , 2007, 11, 1571-1586.	3.4	16
284	High prevalence of BRCA1 deletions in BRCAPRO-positive patients with high carrier probability. <i>Annals of Oncology</i> , 2007, 18, vi86-vi92.	1.2	17
285	Expression of the obesity hormone leptin and its receptor correlates with hypoxia-inducible factor-1 β in human colorectal cancer. <i>Annals of Oncology</i> , 2007, 18, vi116-vi119.	1.2	48
286	Gastrointestinal stromal tumors (GISTs): focus on histopathological diagnosis and biomolecular features. <i>Annals of Oncology</i> , 2007, 18, vi136-vi140.	1.2	52
287	Insulin-like Growth Factor 1 Differentially Regulates Estrogen Receptor-dependent Transcription at Estrogen Response Element and AP-1 Sites in Breast Cancer Cells. <i>Journal of Biological Chemistry</i> , 2007, 282, 3498-3506.	3.4	45
288	Aurora-A overexpression as an early marker of reflux-related columnar mucosa and Barrett's oesophagus. <i>Annals of Oncology</i> , 2007, 18, vi110-vi115.	1.2	8

#	ARTICLE	IF	CITATIONS
289	A phase II study of induction chemotherapy followed by concurrent chemoradiotherapy in elderly patients with locally advanced non-small-cell lung cancer. <i>Anti-Cancer Drugs</i> , 2007, 18, 713-719.	1.4	9
290	Founder mutations in BRCA1 and BRCA2 genes. <i>Annals of Oncology</i> , 2007, 18, vi93-vi98.	1.2	216
291	Role of S128R polymorphism of E-selectin in colon metastasis formation. <i>International Journal of Cancer</i> , 2007, 121, 528-535.	5.1	14
292	<i>BRAF</i> ^{V600E} mutation and p27 ^{kip1} expression in papillary carcinomas of the thyroid $\leq 1\text{ cm}$ and their paired lymph node metastases. <i>Cancer</i> , 2007, 110, 1218-1226.	4.1	81
293	BRCA1 genetic testing in 106 breast and ovarian cancer families from southern Italy (Sicily): a mutation analyses. <i>Breast Cancer Research and Treatment</i> , 2007, 105, 267-276.	2.5	22
294	Molecular detection of TP53, Ki-Ras and p16INK4A promoter methylation in plasma of patients with colorectal cancer and its association with prognosis. Results of a 3-year GOIM (Gruppo Oncologico) Tj ETQq0 0 0 rgBT /Overlook 10 Tf 5		
295	Increased Expression of Leptin and the Leptin Receptor as a Marker of Breast Cancer Progression: Possible Role of Obesity-Related Stimuli. <i>Clinical Cancer Research</i> , 2006, 12, 1447-1453.	7.0	315
296	A new germline mutation in BRCA1 gene in a sicilian family with ovarian cancer. <i>Breast Cancer Research and Treatment</i> , 2006, 96, 97-100.	2.5	8
297	TP53 mutations and S-phase fraction but not DNA-ploidy are independent prognostic indicators in laryngeal squamous cell carcinoma. <i>Journal of Cellular Physiology</i> , 2006, 206, 181-188.	4.1	13
298	TP53 and p16INK4A, but not H-KI-Ras, are involved in tumorigenesis and progression of pleomorphic adenomas. <i>Journal of Cellular Physiology</i> , 2006, 207, 654-659.	4.1	22
299	Y179C, F486L and N550H are BRCA1 variants that may be associated with breast cancer in a Sicilian family: results of a 5-year GOIM (Gruppo Oncologico dell'Italia Meridionale) prospective study. <i>Annals of Oncology</i> , 2006, 17, vii30-vii33.	1.2	10
300	Gemcitabine and oxaliplatin combination chemotherapy in advanced biliary tract cancers. <i>Annals of Oncology</i> , 2006, 17, vii68-vii72.	1.2	50
301	Laser pressure catapulting (LPC): Optimization LPC-system and genotyping of colorectal carcinomas. <i>Journal of Cellular Physiology</i> , 2005, 202, 503-509.	4.1	21
302	Pharmacogenomics in colorectal carcinomas: Future perspectives in personalized therapy. <i>Journal of Cellular Physiology</i> , 2005, 204, 742-749.	4.1	13
303	The TP53 Colorectal Cancer International Collaborative Study on the Prognostic and Predictive Significance of p53 Mutation: Influence of Tumor Site, Type of Mutation, and Adjuvant Treatment. <i>Journal of Clinical Oncology</i> , 2005, 23, 7518-7528.	1.6	331
304	Specific TP53 and/or Ki-ras mutations as independent predictors of clinical outcome in sporadic colorectal adenocarcinomas: results of a 5-year Gruppo Oncologico dell'Italia Meridionale (GOIM) prospective study. <i>Annals of Oncology</i> , 2005, 16, iv50-iv55.	1.2	67
305	Prognostic and predictive factors in colorectal cancer: Kirsten Ras in CRC (RASCAL) and TP53CRC collaborative studies. <i>Annals of Oncology</i> , 2005, 16, iv44-iv49.	1.2	80
306	Weekly paclitaxel (T) and pegylated liposomal doxorubicin (PLD) as first line treatment in metastatic breast cancer (MBC) patient. <i>Journal of Clinical Oncology</i> , 2004, 22, 704-704.	1.6	3

#	ARTICLE	IF	CITATIONS
307	A phase 2 study of oxaliplatin (O) -capecitabine (C) chemotherapy in metastatic breast cancer (MBC) patients pretreated with anthracyclines and taxane. <i>Journal of Clinical Oncology</i> , 2004, 22, 705-705.	1.6	0
308	Weekly paclitaxel (T) and pegylated liposomal doxorubicin (PLD) as first line treatment in metastatic breast cancer (MBC) patient. <i>Journal of Clinical Oncology</i> , 2004, 22, 704-704.	1.6	1
309	A phase 2 study of oxaliplatin (O) -capecitabine (C) chemotherapy in metastatic breast cancer (MBC) patients pretreated with anthracyclines and taxane. <i>Journal of Clinical Oncology</i> , 2004, 22, 705-705.	1.6	0
310	Specific codon 13 K-ras mutations are predictive of clinical outcome in colorectal cancer patients, whereas codon 12 K-ras mutations are associated with mucinous histotype. <i>Annals of Oncology</i> , 2002, 13, 1438-1446.	1.2	196
311	Have p53 gene mutations and protein expression a different biological significance in colorectal cancer?*. <i>Journal of Cellular Physiology</i> , 2002, 191, 237-246.	4.1	18
312	Prognostic significance of p16INK4a alterations and 9p21 loss of heterozygosity in locally advanced laryngeal squamous cell carcinoma. <i>Journal of Cellular Physiology</i> , 2002, 192, 286-293.	4.1	32
313	Kirsten ras mutations in patients with colorectal cancer: the RASCAL II™ study. <i>British Journal of Cancer</i> , 2001, 85, 692-696.	6.4	790
314	DNA aneuploidy and high proliferative activity but not K-ras-2 mutations as independent predictors of clinical outcome in operable gastric carcinoma. <i>Cancer</i> , 2001, 92, 294-302.	4.1	23
315	Prognostic significance of DNA ploidy, S-phase fraction, and tissue levels of aspartic, cysteine, and serine proteases in operable gastric carcinoma. <i>Clinical Cancer Research</i> , 2000, 6, 178-84.	7.0	20
316	Hereditary common cancers: molecular and clinical genetics. <i>Anticancer Research</i> , 2000, 20, 4841-51.	1.1	25
317	Prognostic significance of proliferative activity, DNA ploidy, p53 and Ki-ras point mutations in colorectal liver metastases. <i>Cell Proliferation</i> , 1998, 31, 139-153.	5.3	22
318	Prognostic significance of proliferative activity, DNA-ploidy, p53 and Ki-ras point mutations in colorectal liver metastases. <i>Cell Proliferation</i> , 1998, 31, 139-153.	5.3	20
319	Direct Identification of Each Specific Mutation in Codon 12 and 13 of ki-ras2 by SSCP Analysis. <i>Biochemical and Biophysical Research Communications</i> , 1998, 246, 813-815.	2.1	8
320	Pleomorphic adenoma and adenoid-cystic carcinoma of salivary glands: immunohistochemical assessment of proliferative activity in comparison with flow-cytometric study. <i>Cell Proliferation</i> , 1996, 29, 153-162.	5.3	9
321	Biological characterization of laryngeal squamous-cell carcinoma. <i>Anticancer Research</i> , 1996, 16, 2257-67.	1.1	8
322	Flow cytometric DNA analysis and lysosomal cathepsins b and l in locally advanced laryngeal cancer. Relationship with clinicopathologic parameters and prognostic significance. <i>Cancer</i> , 1995, 76, 1757-1764.	4.1	11
323	Results of the combination of cisplatin, adriamycin and cyclophosphamide in the treatment of ovarian carcinoma. <i>European Journal of Gynaecological Oncology (discontinued)</i> , 1993, 14, 228-33.	0.2	1